Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: A phase I study

Phase I study to determine the MTD of paclitaxel given three times per week during concurrent radiation therapy for stage III non-small cell lung cancer

“…None of the other patients in this group had toxicity greater than grade 2. And none of the limitations designated for the MTD were met for level V. This result is superior to that of other schedules 26,29,30 . Moreover, the non-haematological and haematological toxicity findings observed in this study were similar to those observed with RT alone and much lower than those seen in trials with concurrent continuous-infusion and weekly paclitaxel with or without carboplatin [25][26][27][31][32][33] .…”

Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment

“…Accordingly, several phase I trials have shown that more frequent administration of taxanes was possible. Thus, low-doses of daily paclitaxel can be safely administrated in different clinical settings, such as in combination with radiation therapy in patients with non-small cell lung cancer [228] or in children with cerebral tumours [229]. Moreover, phase II studies have shown the promising efficacy of taxane-based metronomic therapy.…”

How to improve loco-regional control in stages IIIa–b NSCLC?

“…The schedule seems to be safe and median survival is reported in the range of 12-24.9 months. For the schedule with daily paclitaxel, as in arm B, there are four phase I studies trying to establish the maximal tolerated dose (MTD) in combination with radiotherapy [3,[20][21][22]. The phase I/II study preceding the present study found MTD to be 12 mg/m 2 .…”